Physician profile
Grant Jester
NPI 1275952947
$5,734.57
in general payments reported to CMS, 2019-2025
31 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $1,579 · 2022: $770 · 2023: $552 · 2024: $1,303 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,299 · Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Food and Beverage | $961.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,514.08 | 2022-2025 | |
| Genzyme Corporation | $1,519.82 | 2021-2023 | |
| Janssen Biotech, INC. | $385.80 | 2022-2025 | Rybrevant, Darzalex, Carvykti |
| Astellas Pharma US INC | $149.79 | 2019-2025 | Vyloy |
| Pharmacosmos Therapeutics INC. | $114.60 | 2022-2025 | Monoferric |
| Lilly USA, LLC | $99.54 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $89.46 | 2021 | |
| Karyopharm Therapeutics INC. | $83.80 | 2022-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $77.39 | 2022-2023 | |
| Adaptive Biotechnologies Corporation | $67.49 | 2022-2024 | Clonoseq |
| Pharmaessentia USA Corporation | $55.60 | 2024-2025 | Besremi |
| Daiichi Sankyo INC. | $55.56 | 2022-2025 | Vanflyta |
| Pfizer INC. | $52.73 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $51.10 | 2022 | |
| Celgene Corporation | $36.95 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $31.09 | 2022 | |
| Janssen Scientific Affairs, LLC | $29.10 | 2025 | Balversa, Erleada |
| Tempus Ai, INC | $28.38 | 2024 | |
| Dendreon Pharmaceuticals LLC | $27.82 | 2025 | Provenge |
| Kite Pharma, INC. | $27.03 | 2022 | |
| Sumitomo Pharma America, INC. | $26.75 | 2024 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $25.04 | 2024 | Opdivo |
| Caris Mpi, INC. | $23.65 | 2025 | Mi Cancer Seek |
| Delcath Systems | $23.29 | 2025 | Hepzato Kit |
| Coherus Oncology, INC. | $22.94 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.80 | 2022 | |
| Sobi, INC | $22.22 | 2023 | |
| Menarini Silicon Biosystems, INC. | $22.15 | 2024 | |
| Genentech USA, INC. | $21.42 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.32 | 2022 | |
| Merck Sharp & Dohme LLC | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Jester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.